Cargando…

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine

BACKGROUND: Cytarabine (ara-C) is the major drug for the treatment of acute myeloid leukemia (AML), but cellular resistance to ara-C is a major obstacle to therapeutic success. The present study examined enhanced anti-apoptosis identified in 3 newly established nucleoside analogue-resistant leukemic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishi, Rie, Shigemi, Hiroko, Negoro, Eiju, Okura, Miyuki, Hosono, Naoko, Yamauchi, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552348/ https://www.ncbi.nlm.nih.gov/pubmed/33046037 http://dx.doi.org/10.1186/s12885-020-07469-x

Ejemplares similares

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
por: Zeidner, Joshua F., et al.
Publicado: (2021)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Crobu, Valeria, et al.
Publicado: (2019)

YM155 exerts potent cytotoxic activity against quiescent (G(0)/G(1)) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1
por: Ookura, Miyuki, et al.
Publicado: (2017)

Cytarabine/venetoclax: Recurrent Corynebacterium bacteraemia: case report
Publicado: (2022)

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
por: van Eijkelenburg, Natasha K.A., et al.
Publicado: (2018)

Clofarabine exerts antileukemic activity against cytarabine‐resistant B‐cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression
por: Huang, Meixian, et al.
Publicado: (2018)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Modulation of Primary Cilia by Alvocidib Inhibition of CILK1
por: Wang, Elena X., et al.
Publicado: (2022)

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
por: Valdez, B C, et al.
Publicado: (2014)

Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia
por: Ookura, Miyuki, et al.
Publicado: (2018)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
por: Yamauchi, Takahiro, et al.
Publicado: (2014)

Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases
por: Okura, Miyuki, et al.
Publicado: (2020)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

Simultaneous Presentation of Lymphomatoid Granulomatosis and Multiple myeloma in an Immunodeficient Patient with Rheumatoid Arthritis
por: Lee, Shin, et al.
Publicado: (2019)

Use of clofarabine for acute childhood leukemia
por: Pession, A, et al.
Publicado: (2010)

Dual anti-HIV mechanism of clofarabine
por: Daly, Michele B., et al.
Publicado: (2016)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells
por: Zocchi, Loredana, et al.
Publicado: (2018)

Treating refractory leukemias in childhood, role of clofarabine
por: Harned, Theresa M, et al.
Publicado: (2008)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

Clofarabine Experience in Children with Multi-Relapsed Acute Leukemia
por: Karakaş, Zeynep, et al.
Publicado: (2014)

[(18)F] Clofarabine for PET Imaging of Hepatocellular Carcinoma
por: Sergeeva, Olga, et al.
Publicado: (2019)

Mitochondrial Priming of Chronic Lymphocytic Leukemia Patients Associates Bcl-x(L) Dependence with Alvocidib Response
por: Pierceall, William E., et al.
Publicado: (2014)

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
por: Wei, Andrew H., et al.
Publicado: (2019)

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
por: Asada, Noboru, et al.
Publicado: (2023)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Laloi, Louise, et al.
Publicado: (2022)

Successful combination chemotherapy involving clofarabine, cyclophosphamide, and etoposide for pediatric relapsed acute myeloid leukemia: A case report
por: Fujita, Sachio, et al.
Publicado: (2021)

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
por: Tse, Eric, et al.
Publicado: (2011)

Clofarabine desensitization: A case report: Leukemia research reports
por: Hayes, Sarah M., et al.
Publicado: (2017)

Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters
por: Miller, Siennah R., et al.
Publicado: (2021)

Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis
por: Irie, Masahiro, et al.
Publicado: (2021)

Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia
por: Jeha, Sima, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p4koeed8lv1dqfgk1ri0b8k8ga